All In Biotech

Drug Trial Radar · NCT06984094

Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

A Phase 1/2, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1022, a Combination Recombinant RSV-hMPV Protein Subunit Vaccine Candidate, and SCB-1033, a Combination Recombinant RSV-hMPV-PIV3 Protein Subunit Vaccine Candidate in Healthy Older Adults Aged 60-85 Years

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

612

Actual

Start

Jun 18, 2025

Primary completion

Mar 2028

Study completion Jul 2028

Sponsor

Sponsor type
Industry
First posted
May 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).

Conditions

  • RSV Infection
  • Human Metapneumovirus Infection
  • Parainfluenza Infection

Interventions

  • SCB-1019TBiological

    SCB-1019T (bivalent recombinant RSV vaccine candidate) consists of two recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)) and RSV B strain (SCB-1019T(B)).

  • SCB-1022Biological

    SCB-1022 (combination recombinant RSV-hMPV vaccine candidate) consists of three recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), and hMPV (SCB-1021).

  • SCB-1033Biological

    SCB-1033 (combination recombinant RSV-hMPV-PIV3 vaccine candidate) consists of four recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), hMPV (SCB-1021) and PIV3 (SCB-1020).

  • Placebo (saline)Biological

    0.9% saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T (Part 1 and Part 2) or Placebo (Part 3).Time frame: Within 7 days after vaccination
  2. To evaluate the safety and reactogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Part 1 and Part 2) or Placebo (Part 3).Time frame: Within 28 days after vaccination
  3. To evaluate the safety and reactogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Part 1 and Part 2) or placebo (Part 3).Time frame: Throughout the study period, from enrollment up to 2 years follow-up
  4. To evaluate the safety and reactogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Part 1 and Part 2).Time frame: Screening and day 8

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Fusion Clinical Research

    Adelaide, Southern Australia, Australia

  • Paratus Clinical Research

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.